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Extracellular-regulated kinases (ERK1, ERK2) play important roles in the malignant behaviour of breast cancer cells in vitro. In our
present study, 148 clinical breast cancer samples (120 cases with follow-up data) were studied for the expression of ERK1, ERK2 and
their phosphorylated forms p-ERK1 and p-ERK2 by immunoblotting, and p-ERK1/2 expression in corresponding paraffin sections was
analysed by immunohistochemistry. The results were correlated with established clinical and histological prognostic parameters,
follow-up data and expression of seven cell-cycle regulatory proteins as well as MMP1, MMP9, PAI-1 and AP-1 transcription factors,
which had been analysed before. High p-ERK1 expression as determined by immunoblots correlated significantly with a low
frequency of recurrences and infrequent fatal outcome (P¼0.007 and 0.008) and was an independent indicator of long relapse-free
and overall survival in multivariate analysis. By immunohistochemistry, strong p-ERK staining in tumour cells was associated with early
stages (P¼0.020), negative nodal status (P¼0.003) and long recurrence-free survival (P¼0.017). In contrast, expression of the
unphosphorylated kinases ERK1 and ERK2 was not associated with clinical and histological prognostic parameters, except a positive
correlation with oestrogen receptor status. Comparison with the expression of formerly analysed cell-cycle- and invasion-associated
proteins corroborates our conclusion that activation of ERK1 and ERK2 is not associated with enhanced proliferation and invasion of
mammary carcinomas.
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Growth factors or cytokines exert positive and negative effects on
cell proliferation and differentiation. After binding to their
membrane receptors, the message is relayed to the nucleus by a
complex system of intracellular signalling pathways. The majority
of signalling molecules involved in these pathways are kinases,
which are themselves activated by phosphorylation and repressed
by their specific phosphatases. The mitogen-activated protein
kinase (MAPK) signalling pathway includes a cascade of four
groups of kinases (MAPKKKKs, MAPKKKs, MAPKKs and
MAPKs). The MAPK kinase kinase kinases of the first level are
phosphorylated in response to various extracellular stimuli
through interaction with small GTP-binding proteins like Ras,
Raf, etc. The activated enzymes then phosphorylate one of 14
kinases of the second level (the MAPKKKs, that is, Raf proteins,
MEKK1-4, etc.), which themselves activate one of the MAPK
kinases (MEK1 and 2, MKK3–7) of the third level. Finally, these
kinases (MAPKKs) activate MAP kinases, which are then able to
phosphorylate transcription factors, which regulate the expression
of genes involved in cell proliferation or differentiation. Three
different, partly interacting signalling pathways have been
identified in mammalian cells, leading to the activation of three
types of MAP kinases: the MAP kinase JNK (Jun kinase)
phosphorylates c-Jun, JunB, ATF2 and ELK1, etc., P38 activates
ATF2, ELK-1 and MAX, whereas ERK1 and ERK2 phosphorylate
c-Myc, SAP-1, Fra-1 and Fra-2, etc. After phosphorylation, the
MAP kinases translocate to the nucleus where they can activate
nuclear transcription factors.
The role of the MAP kinases ERK1 and ERK2 has been
extensively studied in vitro. Since both proteins, although encoded
by different genes, show high structural and functional similarity,
they are often referred to as ERK1/2. After phosphorylation by the
MAPKKs MEK1 or MEK2, the activated ERK proteins (p-ERK1/2)
form dimers and are translocated from the cytoplasm to the
nucleus (Brunet et al, 1999). MEK–ERK activation in breast cancer
cell lines occurs after binding of oestrogen to its receptor (Collins
and Webb, 1999), stimulation by insulin (Griffiths et al, 1998) or
binding of growth factors like EGF or PDGF (Whitmarsh and
Davis, 1996). In addition, the transformation of mouse mammary
epithelial cells by the oncogenes neu, Ha-ras or myc is
accompanied by ERK upregulation (Amundadottir and Leder,
1998). Experiments with MEK1 inhibitors have shown that ERK
activity correlates with cell proliferation (Seddighzadeh et al, 1999)
and motility (Krueger et al, 2001) in breast cancer cell lines, but
does not influence cell invasion. Moreover, the ratio of ERK1/2 to
p38 in various tumour cell lines determines whether a cell will
proliferate or enter a state of dormancy (Aguirre-Ghiso et al,
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s2003). In a three-dimensional model, treatment of breast cancer
cells with MAPK inhibitors leads to a loss of tumorigenic
properties (Wang et al, 2002), and an intact MAPK pathway is
necessary for alveolar morphogenesis in a reconstitution model
(Niemann et al, 1998).
Transcription factors of the AP-1 family, which include
members of the Jun family (c-Jun, JunB, JunD) and Fos family
(c-Fos, FosB, Fra-1 and Fra-2) have been identified as targets
of MAP kinases (Whitmarsh and Davis, 1996). c-Jun and JunB
are phosphorylated by the Jun N-terminal kinase JNK (Mechta-
Grigoriou et al, 2001). In mouse keratinocytes, ocadaic acid
treatment leads to phosphorylation of JunD and FosB by ERK
and subsequent activation of an AP-1-responsive promoter
(Rosenberger et al, 1999). The Fos-related antigens Fra-1 and
Fra-2 are phosphorylated by MAPK in vitro, which leads to
stabilisation, strong conformational change and an increase in
DNA-binding affinity (Gruda et al, 1994). c-Fos phosphorylation
by MAPK leads to its destabilisation and rapid degradation
(Tsurumi et al, 1995).
In contrast to these in vitro data, there are only few and partly
contradictory reports on the expression and activity of ERK1/2
in clinical tumour tissues. Therefore, we studied the expression
of ERK1 and ERK2 and their phosphorylated forms p-ERK1 and
p-ERK2 by Western blot analysis in 148 mammary carcinomas,
among them 120 cases with follow-up data. In addition, p-ERK1/2
expression was analysed by immunohistochemistry on paraffin
sections from 129 tumours. The results were statistically correlated
with clinical and histological data, the steroid hormone receptor
status as well as recurrence-free and overall survival. Since 75 cases
of our cohort had been characterised before with respect to the
expression of the AP-1 proteins, several cell-cycle regulatory
proteins (cyclin D1 and E, Rb, Rb2, p16, p21, p27), Ki67 and
HER2/neu, the matrix metalloproteinases MMP1 and MMP9 and
members of the uPA–PAI-1 system (Bamberger et al, 1999; Milde-
Langosch et al, 2000; Milde-Langosch et al, 2004), we analysed
possible associations of these factors with ERK1/2 or p-ERK1/2
expression.
MATERIALS AND METHODS
Materials
For our studies on clinical tumour tissues, we analysed 148 breast
cancer samples of the Hamburg University Hospital, Department
of Obstetrics and Gynecology (147 female patients, one male
patient; mean age 57 years, range 25–90 years), taken in the years
1991–2000. The only inclusion criteria for this retrospective study
were the availability of frozen tissue suitable for protein extraction
and (in most cases) follow-up data. Patients treated for primary
breast cancer underwent surgery including lumpectomy and
dissection of axillary lymph nodes by axillary clearance or
modified radical mastectomy. After surgery, the patients received
adjuvant treatment (endocrine treatment and/or anthracycline-
containing chemotherapy as well as radiotherapy) according to
national guidelines.
Histologically, 125 carcinomas were of ductal type, 18 cases were
lobular tumours, four cases had mucinous differentiation and one
case was a tubular carcinoma. Eight tissue samples were from
recurrencies and 140 from primary tumours. Of the primary
tumours, 98 were nodal negative and 41 nodal positive and nodal
involvement was unknown in one case. By immunohistological
oestrogen receptor (ER) assay, 38 cases (26%) were ER negative
and 110 tumours (74%) were ER positive. The pathological staging
of the primary tumours was carried out as recommended by the
UICC. In all, 28 tumours were classified as stage 1, 93 tumours as
stage 2 and 18 tumours as stage 3 or 4. Staging data were
unavailable in nine cases. According to histological examination,
11 specimens were of low malignancy grade (G1), 75 tumours were
classified as G2 and 62 cases were high-grade carcinomas (G3).
Follow-up data were available for 120 patients (median follow-up
time: 74.2 months, range 6–144 months). A total of 29 patients
suffered from recurrence and 21 died from their carcinoma 6–123
months after diagnosis.
After macroscopic examination of the mammary tissue, two
adjacent tumour areas were either fixed in 4% buffered formalin
for 24h prior to dehydration and embedding in paraffin or snap
frozen in liquid nitrogen and stored at  801C until further
processing. Before freezing, the tissue samples were carefully
macroscopically dissected and freed of attached nontumour tissue
in order to achieve at least 50% tumour cells.
The mammary carcinoma cell line MCF7, which was used as
control on Western blots was cultivated as described (Milde-
Langosch et al, 2000).
Immunohistochemistry
For p-ERK1/2 detection, automatic immunostaining on the DAKO
Autostainer was performed using the monoclonal antibody
phospho-p44/42 MAPK (Thr202/Tyr204), clone E10 (Cell Signaling
Technology, Beverly, MA, USA) diluted 1:100 and the ChemMatet
Peroxidase/DAB Detection Kit (DakoCytomation, Glostrup,
Denmark). This antibody was previously used successfully to
visualise phosphorylated ERK1/ERK2 in paraffin-embedded tissue
samples (Adeyinka et al, 2002). Its specificity was also shown in
Western blots (see Results). Serial sections of 4–6mm were cut
from the paraffin blocks and mounted on APES-coated slides,
deparaffinised in xylene and rehydrated in graded alcohol to TBS
(50mM Tris, 150mM NaCl, pH 7.4). Antigen retrieval occurred by
microwave treatment for 20min in 20mM Tris, 10mM citrate and
13mM EDTA, pH 7.8. Blocking of endogenous peroxidase activity
and application of the primary antibody were followed by the
incubation with biotinylated goat anti-mouse immunoglobulins
and streptavidin conjugated to horse-radish peroxidase. DAB
(3,30-diaminobenzidine) chromogen solution and a substrate
buffer containing hydrogen peroxide served as substrate system.
Tissue sections were counterstained by haematoxylin and perma-
nently mounted. As positive control, a tumour with known
expression of the analysed protein in Western blots was used,
whereas the primary antibody was omitted for negative controls.
The evaluation of immunohistochemistry results was performed
independently by two observers. For statistical analysis, the cases
were grouped into only three categories according to p-ERK1/2
immunostaining: negative tumours and those showing only weak
focal expression (0), carcinomas with 1–20% positive tumour cells
(1) and those with more than 20% positivity (2).
The immunohistochemical (IHC) detection of the ER and pro-
gesterone receptors (PR) and the oncogene HER2/neu (c-erbB2)
was performed in paraffin-embedded samples as described
(Bamberger et al, 1999; Milde-Langosch et al, 2000).
Western blot analysis
Protein extraction and Western blots were performed as described
(Bamberger et al, 1999). Briefly, frozen samples were mechanically
disrupted to small pieces, and thoroughly homogenised in ice-cold
lysis buffer with proteinase inhibitor cocktail (50mM Tris, pH 6.8,
1% SDS, 10% sucrose, 10mlml
 1 proteinase inhibitor cocktail;
Sigma, Taufkirchen, Germany) in a mechanical tissue homo-
geniser. The homogenate was centrifuged at 13000g for 5min, and
the protein concentration in the supernatant was determined by
standard methods. Equal amounts of protein (20mg) of each
sample were loaded per well. Electrophoresis was performed in a
10% polyacrylamide separating gel with a 3% stacking gel, and
proteins were transferred to polyvinylidene difluoride membranes
(Immobilon P, Millipore, Eschborn, Germany). After overnight
incubation at 41C in blocking solution (0.1 M maleic acid, pH 7.5,
ERK activation and prognosis in breast cancer
K Milde-Langosch et al
2207
British Journal of Cancer (2005) 92(12), 2206–2215 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s0.15 M NaCl, 0.005% Thimerosal and 1% blocking reagent;
Boehringer Mannheim, Germany), membranes were incubated
for 1h at room temperature with mouse anti-phospho-p44/42
MAPK (clone E10; Cell Signaling Technology, Beverly, MA, USA)
diluted 1:100 or goat anti-ERK1/ERK2 (C126; Santa Cruz
Biotechnology, Heidelberg, Germany) diluted 1:4000. As second-
ary antibody, peroxidase-conjugated anti-mouse-IgG (1:2000) or
peroxidase-conjugated anti-goat-IgG (1:4000; all from Santa Cruz)
were used, which were visualised by chemiluminescence reagents
(Super Signal West Pico kit, Pierce, Rockfort, IL, USA) with
Hyperfilm ECL films (Amersham, Braunschweig, Germany). As
control for comparable exposure of chemiluminescent membranes
and as standard for densitometry, 20mg proteins from the
cell line MCF7 (for ERK1/2) or a carcinoma with moderate
expression (for p-ERK1/2) were always loaded in one well. Band
intensities were quantified by densitometry (GS-700 Imaging
Densitometer, BioRad, Mu ¨nchen, Germany). The different
protein bands for ERK1 and ERK2 or p-ERK1 and p-ERK2 were
measured separately. The intensities of the specific protein bands
were calculated as percent intensity of the control sample and
corrected for equal actin loading. According to the resulting
expression levels, the 148 samples were divided into three groups
of 48–50 cases for each protein in order to obtain groups of
similar sizes representing tumours with weak, moderate and
strong expression.
In all, 75 samples had been analysed before with respect to the
expression of the AP-1 proteins c-Jun, JunB, JunD, c-Fos, FosB,
Fra-1 and Fra-2. Western blot conditions for all AP-1 proteins have
been described in our previous publication (Bamberger et al,
1999). Fra-1 and Fra-2 are characterised by two or more bands
in Western blots representing different phosphorylation states,
which were evaluated separately as described (Milde-Langosch
et al, 2004). For all AP-1 proteins, the samples were divided into
two groups of similar size (weak and strong immunoreactivity)
according to their expression levels for statistical correlations.
The expression of the cell-cycle regulatory proteins cyclin D1,
cyclin E, Rb, Rb2, p16, p21, p27, the proliferation marker Ki67 and
of the invasion-associated proteins MMP1, MMP9 and PAI-1 had
also been analysed before by Western blot analysis and
densitometry. For statistical analysis, the samples were divided
into two or three groups with similar expression levels as described
(Milde-Langosch et al, 2000, 2004).
Statistics
The SPSS11.0 program was used for calculation of inter-relation-
ships between the analysed ERK and p-ERK proteins and
histological or clinical factors as well as previously analysed
proteins by w
2 test. For the prognostic parameters, the
following groups were compared: histological grade G1 and 2 vs
G3 and 4, stage I and II vs IIIand IV, nodal involvement vs nodal-
negative tumours, ER-negative tumours vs ER-positive cases,
PR-negative vs PR-positive carcinomas, HER2/neu-negative/weak
results vs moderate/strong HER2neu staining, recurrence-free
cases vs patients with recurrence during the follow-up period,
cases with fatal outcome vs patients who were alive at the end of
follow-up.
By the same program, Kaplan–Meier analysis of overall and
relapse-free survival in groups with different ERK and p-ERK
expression was performed. Multivariate Cox’s regression analysis
was performed using the likelihood ratio test and forward selection
of the variables (inclusion limit 10%). Probability values less than
0.05 were regarded as statistically significant. Overall survival was
defined between the time interval between the operation and death
from breast cancer. Similarly, recurrence-free survival is the time
between the operation and the detection of local relapse or distant
metastases.
RESULTS
p-ERK1/2 immunohistochemistry
Immunohistochemistry for phosphorylated ERK1/ERK2 was
performed with 129 mammary carcinomas, two lymph node
metastases and eight normal mammary tissue samples. Positive
staining was mostly nuclear as expected.
Normal ductal or lobular epithelia were either p-ERK1/2-
negative or positive in single epithelial cells. Positive immunos-
taining in normal tissue samples was often found in myoepithelial
cells surrounding the epithelia and in smooth muscle cell bundles,
and was detected less frequently in stromal fibroblasts (Figure 1A).
In carcinoma tissue samples, normal ductal structures adjacent to
the tumour frequently showed cytoplasmic and nuclear p-ERK
staining (Figure 1B)
Cells of ductal carcinoma in situ (DCIS) areas in the
neighbourhood of invasive tumours were either negative
(Figure 1B) or positive in the outer cell layer of the cell mass.
Invasive carcinomas were often characterised by a striking
heterogeneity showing areas of strong nuclear immunoreactivity in
tumour cells next to p-ERK1/2-negative regions. Generally, solid
tumour masses were mostly negative or weakly stained, whereas
p-ERK1/2 positivity was often observed near the invasion front
(Figure 1C) or in small tumour cell groups. In Figure 1, examples
of tumours with strong (Figure 1F) and absent immunostaining
(Figure 1D) are shown. Stromal fibroblasts exhibited different
degrees of p-ERK positivity and often displayed strong immuno-
staining independent of the pERK1/2 expression in tumour cells
(Figure 1D). In contrast to the mostly nuclear staining in most
cases, strong cytoplasmic reactivity was detected in one tumour
(Figure 1E). Both lymph node metastases analysed in this study
were negative for p-ERK1/2. There was no detectable difference in
p-ERK immunoreactivity between paraffin sections from older
blocks (from 1991 to 1994) vs newer ones, which indicates that the
phosphoepitopes remained intact in paraffin-embedded tissue
during long time spans.
For statistical analysis, the cases were divided into three groups:
p-ERK-negative or focally positive tumours (n¼39), tumours with
positive pERK staining in less than 20% (n¼43) and carcinomas
with more than 20% positive tumour cells (n¼47). Stronger
p-ERK1/2 immunostaining in tumour cells was significantly
associated with early-stage (P¼0.020) and negative nodal status
(P¼0.004; Table 1). There were no associations of p-ERK1/2
immunoreactivity with age, histological type and grading, ER and
PR status, as well as with Ki67 and HER2/neu expression (not
shown).
p-ERK1 and p-ERK2 Western blot results
For immunoblots, the same antibodies used for immunohisto-
chemistry were used, resulting in two bands of 42 and 44kDa
(Figure 1G). Densitometry and statistical analysis were performed
separately for both kinases. As positive control, a carcinoma
sample showing moderate p-ERK expression was chosen. Rela-
tively to this control, the mean p-ERK1 expression in the
carcinomas was 125.9% (range 1–683%), whereas the mean
expression of p-ERK2 was 85.8% (range 1–587%).
In the normal tissue samples (n¼11), high variations of p-
ERK1/2 expression were observed. The mean expression levels in
this group were 174% for p-ERK1 (range 1–863%) and 126.5% for
p-ERK2 (range 1–344%). In pairs of tumour and adjacent normal
tissues, p-ERK1/2 expression was either higher (n¼2), weaker
(n¼2) or nearly identical (n¼2) in the nontumour samples.
For statistical analysis, the carcinomas were divided into three
groups of similar size (n¼48–50 cases) according to their
expression of p-ERK1 and, separately, p-ERK2. There were
significant correlations of both phosphorylated kinases with each
ERK activation and prognosis in breast cancer
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never represent proteins from tumour cells only, but always also
include proteins from stromal fibroblasts and, partly, myoepithe-
lial or ductal epithelial cells which might also express activated
kinases, we found correlations of p-ERK1/2 expression in Western
blots with IHC p-ERK1/2 expression in tumour cells (P¼0.030 and
0.048 for p-ERK1 and p-ERK2, respectively; not shown). This
indicates that most of the activated ERK1 and ERK2 in the protein
extracts used for immunoblots are from tumour cells.
By w
2 test, we found a significant inverse correlation of p-ERK2
expression with tumour stage (P¼0.014; Table 1). No significant
correlations with age, histological type and grade, nodal involve-
ment, ER and PR status, Ki67 expression and HER2/neu positivity
were found.
ERK1 and ERK2 Western blot results
The mouse antibody used in this study reacts with ERK1 (p44)
and, to a lesser extent, with ERK2 (p42). Both proteins were
analysed on Western blots and quantified separately by densito-
metry (Figure 1G). In comparison with the mammary carcinoma
cell line MCF7, which served as positive control and was set as
100%, the mean expression levels in the carcinomas were 183% for
ERK1 (range 1–863%) and 80% for ERK2 (range 1–314%).
In the normal mammary tissue samples (n¼7), mean expres-
sion levels of 57.3% for ERK1 (range 3–99%) and 42.0% for ERK2
(range 5–93%) were observed. In pairs of tumour and normal
tissue, ERK1 expression was higher in the tumour in five of six
cases, and ERK2 expression was higher in all carcinomas.
Statistical analysis was performed as described for p-ERK1/2.
There was a highly significant correlation of ERK1 with ERK2
protein levels (Po0.001). In addition, significant associations were
found for ERK1 with p-ERK1 (Po0.001) and p-ERK2 (P¼0.001)
as well as for ERK2 with p-ERK2 (P¼0.014). With patient’s age,
histological type, grading, stage, PR status, Ki67 and HER2/neu
expression and nodal status, no significant associations were found
(not shown). For the ER status, a positive correlation with ERK1
expression was observed (Table 1).
Correlation of ERK1/2 and p-ERK1/2 expression with
follow-up data
During the follow-up period, 29 patients suffered from a
recurrence and 21 patients died from their disease. By w
2 test, we
found significantly higher numbers of recurrences in cases with
negative/focal p-ERK1/2 staining by immunohistochemistry and
significantly more frequent death of disease (DOD) or relapse
in patients with weak p-ERK1 expression in Western blots. For
p-ERK2 expression, only a trend pointing to an inverse correlation
Figure 1 p-ERK1/2 and ERK1/2 detection by immunohistochemistry (A–F) and Western blots (G). (A) Positive p-ERK staining in myoepithelial cells
around normal terminal lobules in tumour-free mammary tissue from a 65-year-old patient,  200. (B) p-ERK-negative staining result in DCIS areas of a
moderately differentiated carcinoma. Strong positivity in ductal epithelia (arrow),  200. (C) Nuclear p-ERK staining in tumour cells at the invasion front
of a poorly differentiated ductal carcinoma,  400. (D) p-ERK-negative tumour cells and positive stromal fibroblasts in a moderately differentiated
ductal carcinoma,  400. (E) Perinuclear and cytoplasmic p-ERK staining in a poorly differentiated ductal carcinoma,  400. (F) Strong, mainly
nuclear immunostaining in tumour cells of a moderately differentiated ductal carcinoma,  400. (G) Western blot analysis of ERK1/ERK2 (p44/p42) and
p-ERK1/p-ERK2. T: tumour sample; N: normal mammary tissue sample; C: positive control sample.
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Kaplan–Meier analysis showed a significantly longer recurrence-
free and overall survival in patients with high p-ERK1/2 expression
(420% tumour cells) as determined by immunohistochemistry
and in cases with strong p-ERK1 expression as measured by
Western blots and densitometry (Figure 2). For p-ERK2, ERK1 and
ERK2, the differences in overall and relapse-free survival were not
significant (not shown).
In order to analyse if the expression of phosphorylated ERK
proteins is an independent prognostic indicator, a multivariate
analysis also including the variables stage, grading, ER status and
nodal involvement was performed. By Cox’s regression analysis of
the Western blot results for p-ERK, high-stage and low p-ERK1
expression were independent predictors of early recurrence,
whereas poor differentiation (G3) and low p-ERK1 expression
were significant predictors of short overall survival (Table 2).
Regarding the IHC results, negative/weak p-ERK expression was
the only independent prognostic parameter for early relapse,
whereas high grading and negative/weak p-ERK immunoreactivity
were independent predictors of DOD (Table 2).
Correlations with the expression of cell-cycle regulatory
proteins and Ki67
The expression of the cell-cycle promoting cyclins D1 and E,
the cell-cycle inhibitors Rb, Rb2, p16, p21 and p27, and the
proliferation marker Ki67 had been studied before by Western blot
analysis or, for Ki67, by immunohistochemistry in 75 tumours
from our cohort (Milde-Langosch et al, 2000). In order to analyse
if there are correlations with the expression levels of ERK1/2 or
p-ERK1/2, statistical analysis by w
2 tests was performed.
Table 1 Correlations of ERK1, ERK2, p-ERK1and p-ERK2 expression with histological and clinical tumour parameters, cell-cycle regulatory and invasion-
associated proteins and AP-1 transcription factors
Correlation with: (detection method) n¼ p-ERKl/2 (IHC) p-ERKl (WB) p-ERK2 (WB) ERK-I (WB) ERK-2 (WB)
(A) P-values after w
2 test
a
Clinical/histological parameters
Age (20–50 vs 450 years) 148 NS NS NS NS NS
Stage (I vs II vs III/IV) 140 0.020* NS 0.014* NS NS
Histol. type (ductal vs others) 148 NS NS NS NS NS
Nodal status (positive vs negative) 139 0.003* NS NS NS NS
ER status (IHC; pos. vs neg.) 146 NS NS NS 0.007 NS
Recurrence 120 0.024* 0.007* 0.062* NS NS
DOD 120 0.072* 0.008* 0.063* NS NS
Proliferation-associated proteins (WB)
Cyclin Dl 75 0.077* NS NS 0.023 0.014
Rb 75 NS NS NS NS 0.031
Rb2 75 NS NS NS NS 0.094
p27 68 NS NS NS NS NS
pl6 75 NS NS NS NS 0.023
p2l 75 NS NS NS NS NS
Cyclin E 75 NS NS NS NS NS
Ki67 75 NS NS NS NS NS
Invasion-associated proteins (WB)
MMP9 74 NS 0.039* NS NS NS
MMP1 proenzyme 74 NS NS NS 0.090 NS
MMP1 active 74 NS 0.020 NS NS NS
PAI-1 75 NS NS NS 0.029 NS
AP-I transcription factors (WB)
c-Jun 75 NS NS NS NS NS
JunB 75 NS NS NS NS NS
JunD 75 NS 0.062* NS NS 0.008
c-Fos 75 NS NS NS NS 0.038
FosB 75 NS 0.073 NS 0.015 NS
Fra-1 75 NS NS NS NS NS
Fra-1 (phosph.) 75 NS 0.086* NS NS NS
Fra-2 75 NS NS NS 0.035 0.048
Fra-2 (phosph.) 75 NS NS NS NS NS
High expression ofy. y. is significantly associated with:
(B) Overview of significant statistical associations
b
p-ERK (IHC) Early stage; negative nodal status; low frequency of recurrence
p-ERK1 (WB) Low frequency of recurrence and DOD; low MMP9 and high MMPI expression levels
p-ERK2 (WB) Early stage
ERKl (WB) Positive ER status; high cyclin D1, PAI-1, FosB and Fra-2 expression
ERK2 (WB) High cyclin Dl, Rb, p16, JunD, c-Fos and Fra-2 expression
ER¼estrogen receptor; NS¼not significant; WB¼Western blot results; IHC¼immunohistochemical data; DOD¼death of disease.
aP-values after w
2 tests below 0.1 are
shown. Statistically significant correlations are given in bold letters and inverse correlations are indicated by asterisks. The formation of groups for statistical analysis is described in
Materials and Methods.
bOnly correlations with Po0.05 are included.
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sThere were significant associations of ERK1 expression with
cyclin D1 protein levels and of ERK2 expression with cyclin D1,
p16 and Rb immunoreactivity. In addition, weak, nonsignificant
associations (P40.05) of ERK2 and Rb2 expression and of high
p-ERK1/2 and low cyclin D1 levels were found (Table 1). No
correlations of ERK and p-ERK levels with p27, p21, cyclin E or
Ki67 expression were detected.
Correlations with the expression of invasion-associated
proteins
In a prior study, we examined the expression of the matrix
metalloproteinases MMP9 (gelatinase B) and MMP1 (collagenase 1)
and the inhibitor of the urokinase plasminogen-activator
(PAI-1) in patients of the same cohort (Milde-Langosch et al,
2004). For MMP1, protein levels of the proenzyme and the cleaved,
active enzyme were analysed separately by Western blots and
densitometry.
By statistical evaluation, we found significant correlations of
high p-ERK1 protein levels with low MMP9 and high MMP1 (active
form) expression. In addition, high ERK1 expression was
associated with stronger PAI-1 immunoreactivity. In contrast,
ERK2 and p-ERK2 expression and p-ERK1/2 IHC staining were not
associated with any of the analysed invasion-associated factors.
Correlations with the expression of AP-1 transcription
factors
The expression of the Jun proteins c-Jun, JunB and JunD as well as
the Fos family members c-Fos, FosB, Fra-1 and Fra-2 in the
analysed mammary tumour tissues was described in our prior
publication (Bamberger et al, 1999). Since some of these
transcription factors are phosphorylated by activated ERK proteins
leading to an increased DNA-binding and transactivating capacity,
we compared the expression levels of the AP-1 proteins with those
obtained for ERK1/2 and p-ERK/2 in the present study.
For the phosphorylated, active kinases, no significant correla-
tions with AP-1 transcription factors were found. High p-ERK1
expression as found in Western blots was only weakly associated
with high FosB and low JunD levels (Table 1). In contrast, the
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Figure 2 Kaplan–Meier plots of overall survival (A and B) and recurrence-free survival (C and D) in groups defined by p-ERK1/2 immunohistochemistry
(A and C) and p-ERK1 Western blots and densitometry (B and D). The cases were grouped as described in the Materials and Methods.
ERK activation and prognosis in breast cancer
K Milde-Langosch et al
2211
British Journal of Cancer (2005) 92(12), 2206–2215 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sunphosphorylated ERK1 showed a significant positive correlation
with FosB and Fra-2 expression, and ERK2 was associated with
JunD, c-Fos and Fra-2. No significant correlation with the
phosphorylated forms of Fra-1 and Fra-2 was found, except a
weak trend for a higher phosphorylated Fra-1 band intensity in
tumours with absent/weak p-ERK1 expression (Table 1).
DISCUSSION
Experimental data with breast cancer cell lines have shown that
MAP kinases are involved in normal alveolar morphogenesis
(Wang et al, 2002), and that high ERK activity correlates with
proliferation and motility of breast cancer cells (Seddighzadeh
et al, 1999). In contrast, there are only few studies dealing with
ERK1/2 expression and activation in human clinical tumour
tissues.
Investigations on nonmammary tumour types gave partly
controversial results regarding the prognostic significance of
ERK expression: in salivary gland mucoepidermoid carcinomas,
high levels of phosphorylated ERK1/2 in tumour cells were
associated with early progression (Handra-Luca et al, 2003). In
contrast, ovarian tumour patients with high ERK1/2 and p-ERK1/2
expression in pleural effusions had a better overall survival than
women with low ERK or p-ERK values (Givant-Horwitz et al,
2003). Interestingly, ERK expression and activity in these cases was
increased after chemotherapy. In prostate cancer, p-ERK1/2
staining intensity in tumour cells declined with disease progres-
sion (Malik et al, 2002), and in small cell lung carcinomas, tumours
with cytoplasmic expression of p-ERK had a better prognosis than
p-ERK-negative cases, whereas no prognostic value was found for
nuclear immunoreactivity (Blackhall et al, 2003).
With respect to breast tumours, earlier studies suggest an
involvement of activated MAP kinases in carcinogenesis and
progression. Sivaraman et al (1997) reported an increased
enzymatic MAPK activity in cytosols from 12 mammary carcino-
mas as compared to normal tissues or benign lesions, and Salh
et al (1999) found increased ERK1 and ERK2 amounts after
immunoprecipitation relative to normal tissue samples, although
ERK2 staining intensity in immunohistochemistry was actually
reduced in tumour cells. These results can be partly explained by
the lower percentage of epithelial cells in the normal tissue
samples. Our IHC and Western blot data point to high variations
between the tumours with a downregulation of p-ERK1/2
expression in many carcinomas and overexpression of the
activated kinases in other tumours.
In another study, MAPK activity in cytosols from 131 mammary
carcinomas was assayed by an enzymatic test and found to
correlate positively with nodal involvement, and with a higher risk
of relapse, although these associations were not significant in uni-
and multivariate analysis (Mueller et al, 2000). This is in contrast
to our results where high expression of activated ERK1/2 is
significantly associated with a long recurrence-free survival. One
explanation for this apparent discrepancy might be the different
processing of the breast cancer samples: for the biochemical test,
the specimens were pulverised in the presence of a mild lysis buffer
Table 2 Multivariate analysis for relapse-free and overall survival as a function of p-ERK1/2 expression
a
Category Beta (s.e.) Relative risk (Cl) P-value
Relapse-free survival: p-ERK1 (Western blot)
Stage
Stage 1 0.018
Stage 2  0,105 (0.534) 0.900 (0.32–2.56) 0.843
Stages 3+4 1.406 (0.644) 4.080 (1.15–14.42) 0.029
p-ERK1 (WB)
Strong 0.049
Moderate 0.871 (0.691) 2.390 (0.62–9.26) 0.208
Weak 1.515 (0.648) 4.551 (1.28–16.21) 0.019
Relapse-free survival; p-ERK1/2 (immunohistochemistry):
p-ERK1/2 (IHC)
420% positive 0.017
1–20% positive 2.111 (0.771) 8.257 (1.82–37.41) 0.007
Negative/focal 2.158 (0.795) 8.656 (1.82–41.15) 0.006
Overall survival; p-ERK1 (Western blot):
Grading
G1+2
G3 0.871 (0.459) 2.389 (0.97–5.87) 0.058
p-ERK1 (WB)
Strong 0.038
Moderate 0.449 (0.733) 1.57 (0.37–6.59) 0.540
Weak 1.414 (0.646) 4.11 (1.16–14.59) 0.029
Overall survival; p-ERK1/2 (immunohistochemistry):
Grading
G1+2
G3 1.170 (0.546) 3.22 (1.11–9.40) 0.032
p-ERK1/2 (IHC)
420% positive 0.058
1–20% positive 1.799 (0.786) 6.04 (1.30–28.20) 0.022
Negative/focal 1.864 (0.854) 6.45 (1.21–34.40) 0.029
s.e.¼standard error; CI¼95% confidence interval; WB¼Western blot; IHC¼immunohistochemical.
aCox’s regression analysis using forward selection of the variables including
stage, grading, ER status and nodal involvement together with either p-ERK1 expression as measured by immunoblots or p-ERK1/2 expression in tumour cells as determined by
immunohistochemistry.
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sfollowed by ultracentrifugation, and only the supernatant was used
for MAP kinase measurements. In contrast, we used a buffer
containing the strong detergent SDS for protein extraction from
tissue samples in order to solubilise as many proteins as possible.
In our experience, mild lysis buffers are not suitable for assaying
nuclear proteins, since cell nuclei remain intact and are then
sedimented by high-speed centrifugation. As members of the
intracellular signalling pathways, the unphosphorylated MAP
kinases are localised in the cytoplasm. After phosphorylation,
they translocate to the nucleus where they can activate various
transcription factors (Brunet et al, 1999). Therefore, an enzymatic
test for MAP kinase activity in cytosolic extracts probably
measures only a fraction of the total p-ERK activity.
From a technical view, our present investigation is more
comparable to two IHC studies, which both conclude that activated
ERK1/2 might be involved in tumour progression and a worse
prognosis of breast cancer patients. Both studies differ in the
antibodies used: in the first (Adeyinka et al, 2002), a polyclonal
phospho-p44/p42 (Thr 202/Tyr 204) antibody (New England
Biolabs, Frankfurt a.m., Germany) was employed, whereas in the
second (Gee et al, 2001), a polyclonal anti-ACTIVE
TM MAPK
antibody (Promega, Mannheim, Germany) for dually phosphory-
lated ERK1/2 forms was used. In our study, we used a monoclonal
phospho-p44/p42 (Thr 202/Tyr 204) antibody (Cell Signaling
Technology).
Yet, variations in the used antibodies are probably not the main
reason for different results. In the IHC study of Adeyinka et al
(2002), follow-up data were presented for only 29 ER-positive,
nodal-negative patients, which were treated with tamoxifen. No
significant differences in response to therapy were observed
between these groups, indicating that activated MAPK is not a
marker of endocrine sensitivity. Comparing the p-MAPK positivity
rates of 90% in a group of nodal-positive tumours (n¼21) and
48% in a group of mixed nodal status, the authors conclude that
activated MAPK might be a marker of a poor prognosis. This
assumption was not confirmed by statistical methods like uni- or
multivariate analysis. In another study (Gee et al, 2001), 90
carcinomas were analysed by IHC with a positivity rate of 72% and
an intratumour heterogeneity similar to our observations. High
IHC p-ERK1/2 reactivity in these cases was associated with poor
response to antihormonal therapy and shorter survival in ER-
positive cases and in all patients (Gee et al, 2001). In addition,
multivariate analysis revealed a significant correlation of short
survival and positive p-MAPK immunostaining in the subgroup
of ER-positive cases. In contrast to our cohort, all tumours in this
study were either locally advanced or metastatic and treated with
antihormonal therapy, and 82% of the patients died during follow-
up (in contrast to 17.5% in our group). Therefore, a comparison
of both studies is difficult and additional investigations will be
needed to clarify the discrepancies.
In contrast to these studies, our present data have shown that
high p-ERK1 expression in breast cancer tissues is an independent
and significant predictor of a favourable prognosis. The correla-
tion of negative p-ERK staining results with shorter relapse-free
survival was independently found using two technical approaches
– the IHC p-ERK1/2 detection and Western blot analysis – which
corroborates this conclusion. Although for the other kinase,
p-ERK2, only a weak, nonsignificant correlation with relapse or
survival was found, the association of high p-ERK2 expression
with early stage does not point to a role of this kinase in tumour
progression.
The major advantage of Western blot analysis with p-ERK1/2
antibodies is the possibility to differentiate between both activated
kinases (p-ERK1 and p-ERK2), whereas its major drawback is the
failure to discriminate between protein expression in tumour cells
and accompanying nonmalignant cell types. By immunohisto-
chemistry, p-ERK1/2 protein expression in tumour cells only was
calculated. By the parallel use of both methods and the correlations
of the results, we could confirm that the p-ERK proteins detected
by Western blots are mostly derived from tumour cells. In
addition, our data suggest that the correlations of the immuno-
histochemically detected p-ERK1/2 levels with recurrence-free
survival are mainly due to p-ERK1 expression since no statistically
significant correlations were found for p-ERK2 (Table 1).
Interestingly, high p-ERK1 protein levels also show correlations
with low MMP9 and strong MMP1 expression. Similar to ERK1/2,
both MMPs and PAI-1 are expressed by tumour cells and stromal
cells in varying proportions (Brummer et al, 1999; Dublin et al,
2000). In a prior study with the same cohort, expression of the
active MMP1 enzyme was associated with ER positivity and a
negative nodal status, whereas high MMP9 protein levels
correlated with nodal involvement (Milde-Langosch et al, 2004).
Since MMP9 is well known as a negative prognostic indicator
(Kupferman et al, 2000), the association of low MMP9 with high
p-ERK1 levels fits to our result that high ERK activity is associated
with long recurrence-free survival times in breast cancer, although
it is no proof of a causal relationship between both factors.
As for the analysed cell-cycle regulatory proteins and Ki67, there
were no significant associations with p-ERK1 or p-ERK2 expres-
sion, which indicates that there is no direct involvement of these
activated kinases in breast cancer proliferation. In immunoblots,
all of the cell-cycle regulators are only weakly expressed in normal
mammary tissue samples relative to most carcinomas (Milde-
Langosch et al, 2000). Therefore, the results are probably not due
to nontumour cells within the analysed tissue samples. Interest-
ingly, experiments with the breast cancer cell line MCF7 have
shown that inhibition of proliferation by TPA is accompanied by
high ERK2 expression (Alblas et al, 1998). This is in agreement
with our results, which are in favour of a growth-inhibiting role of
ERK1/2 in breast cancer cells.
The results obtained with the unphosphorylated kinases ERK1
and ERK2 differ from those obtained for the activated enzymes.
We found no significant correlations of these proteins with
classical prognostic and histological parameters and with recur-
rence-free or overall survival. Instead, high expression of both
enzymes was associated with overexpression of cyclin D1, and
ERK2 levels correlated with Rb and p16 expression. Since cyclin D1
is associated with a favourable prognosis in breast cancer (Barnes
and Gillett, 1998) and Rb and p16 are well-known tumour-
suppressor genes, these results underline that ERK1 and ERK2 are
not involved in proliferation in mammary carcinomas. Yet, the
association of ERK1 with PAI-1 expression indicates that ERK1
might be involved in the regulation of invasion of tumour cells.
An additional aspect of this study was the comparison of ERK1/
2 proteins and their downstream effectors, the AP-1 transcription
factors. Similar to most cell-cycle proteins, the expression of c-Fos,
Fra-1, Fra-2 and, to a lesser degree, FosB is absent or weak in
normal mammary tissue samples, and the data obtained from
Western blots with breast cancer specimens probably reflect their
expression in tumour cells (Bamberger et al, 1999). Since Gruda
et al (1994) reported a stabilisation of Fra-1 and Fra-2 after
phosphorylation by MAP kinases, we expected correlations of
these Fos-related proteins or their phosphorylated forms with
activated ERKs (p-ERK1 and -2). Yet, we only found weak,
nonsignificant associations of strong p-ERK1 expression with high
FosB and low JunD and p-Fra-1 protein levels. Fra-1 and Fra-2 are
phosphorylated not only by MAP kinases but also by PKA, PKC
and cdc2 (Gruda et al, 1994). In contrast to the other kinases,
MAPK induce a conformational change, which results in a
strikingly reduced mobility (Gruda et al, 1994). The position of
the p-Fra-1 band observed in our tumour samples (Bamberger
et al, 1999) indicates that the protein was not phosphorylated by
ERK1/2, but probably by another kinase. Thus, phosphorylation of
Fra-1 and Fra-2 by activated ERK1/2 obviously does not play a
major role in the regulation of AP-1 activity in mammary
carcinomas in vivo.
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expressed in more differentiated, hormone-receptor-positive
tumours (Milde-Langosch et al, 2003). Thus, the comparison of
p-ERK expression with AP-1 protein results confirms our
conclusion that overexpression of these activated MAP kinases is
associated with a better prognosis. The correlations found for the
nonphosphorylated ERK proteins with c-Fos and Fra-2 expression
(Table 1) might not reflect an effect of MAP kinases on AP-1
proteins, since these associations were not found with the activated
enzymes, but rather point to a regulation of ERK expression by
AP-1 or common regulatory mechanisms.
Knowing the in vitro data that have shown an involvement of
ERK1/2 activation in proliferation and motility of breast cancer
cells, our experiments with clinical tumour tissues have surpris-
ingly shown opposite results since high levels of the activated
kinases were associated with a better prognosis. MAP kinases are
members of the signalling pathway, which transduces signals from
membrane receptors to the transcription machinery in the nucleus.
During tumour progression, the cells often become more and more
independent of these extracellular stimuli. In breast cancer,
tumour growth is stimulated by oestrogens during tumorigenesis,
but highly malignant and progressive tumours are often char-
acterised by a loss of ERs and hormone-independent growth.
Similarly, the phosphorylation of target genes by activated
ERK1 or ERK2 might be dispensable in advanced mammary
carcinomas. Therefore, attempts to target the MEK-ERK pathway
for therapy of breast cancer might not be successful in such cases
(Shen and Brown, 2003). Additional investigations will be
necessary to analyse the underlying mechanisms leading to strong
proliferation and invasion in these tumours. Furthermore, the
relevance of phosphorylated ERK proteins as prognostic or
predictive indicators in breast cancer should be analysed in future
larger studies.
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